OpenClinica

Contact for Pricing

Twitter

Facebook

Copy Link

OpenClinica empowers clinical research professionals with smart data management and automation tools for efficient clinical trials.

How OpenClinica can help you:

Enhance data management efficiency and accuracy.
Automate clinical trial processes to save time and reduce errors.
Improve participant engagement through patient-reported outcomes and electronic clinical outcome assessments (ePRO and eCOA).
Integrate seamlessly with EHR for real-time data acquisition.
Access to advanced reporting dashboards and data analysis for informed decision-making.

Why choose OpenClinica: Key features

Electronic Data Capture & Clinical Data Management.
EHR eSource Integration.
ePRO and eCOA for comprehensive patient insights.
Randomization & Supply Management for study efficiency.
Powerful reporting and analytical tools.

Who should choose OpenClinica:

Data managers seeking efficient trial management solutions.
Clinical researchers aiming for higher accuracy and engagement.
Study participants looking for user-friendly trial participation methods.
Organizations requiring reliable data acquisition and analysis tools.

About OpenClinica

Website

https://www.openclinica.com/

Release Date

March 2024

Pricing

Contact for Pricing

Related fields

Related News

Eisai Selects Medidata's Clinical Data Studio to Enhance and Modernize Clinical Trial Efficiency and Patient Experience

AI-enhanced solution will help Eisai accelerate data review and reconciliation by 80% Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced Eisai Inc. ("Eisai"), the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., as one of the first customers to harness its recently announced AI-driven Medidata Clinical Data Studio. Eisai Inc., will leverage this innovative data experience to gain unprecedented control over its clinical data, enable the execution of scalable and complex clinical trials, and enhance patient experience. "We've included Medidata's Clinical Data Studio in our clinical trial management platform given its ability to break down data silos and seamlessly integrate into our current software stack, while maintaining quality and integrity across all data sources," said Shobha Dhadda, Ph.D. chief clinical science & operations officer, at Eisai. "Having a suite of technology solutions capable of processing diverse clinical and patient data types provides increased efficiencies without sacrificing quality or needing additional resources." Clinical Data Studio is powered by the Medidata Platform, the industry's only unified platform that centrally manages all data sources, improving data reliability across the entire clinical trial ecosystem. By seamlessly integrating data from both Medidata sources, including Medidata Rave EDC, and non-Medidata sources, such as labs or another electronic data capture system, Clinical Data Studio streamlines the import process and enables automatic validation through configured data transfer agreements. Utilizing AI, it mitigates challenges posed by disparate data systems and offers up to 80 percent faster data review while providing a comprehensive view of patient data that can be concurrently reviewed, visualized, and acted on. "Through Clinical Data Studio, Eisai is enabling healthcare stakeholders to overcome the complexities of modern clinical trials and foster collaboration on cleaner, more actionable data," said Janet Butler, executive vice president, global head of sales, Medidata. "By delivering a unified AI-driven data management and analytics experience, we are enabling study teams to identify potential data issues faster and gain a more accurate understanding of the patient." About Medidata Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 33,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,200+ customers trust Medidata's seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata. About Dassault Systèmes Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all -consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com. © Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval. About Eisai Inc. Eisai Inc., a human health care company, is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. headquartered in Nutley, N.J. Dedicated to oncology and neurology, its U.S. operations include research & development; manufacturing; global supply & logistics; and commercial activities. Learn more: https://us.eisai.com; Follow us on X and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20240724837236/en/

Market Screener

Thu, 25 Jul, 8:03 AM UTC

eClinical Solutions Market to Reach USD 22.35 Billion by 2031, Growing at 13.4% CAGR | SkyQuest Technology

Westford, USA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the eClinical Solutions market will attain a value of USD 22.35 billion by 2031, with a CAGR of 13.4% over the forecast period (2024-2031). Growing volume of data in the healthcare space and the need for effective solutions to manage the same are driving eClinical solutions market growth. Rapid digitization of the healthcare industry is slated to create new opportunities for eClinical solution providers in the future. Download a detailed overview: https://www.skyquestt.com/sample-request/eclinical-solutions-market Browse in-depth TOC on "eClinical Solutions Market" Pages - 265Tables - 123Figures - 77 eClinical Solutions Market Overview: Report CoverageDetailsMarket Revenue in 2023$ 8.15 billionEstimated Value by 2031$ 22.35 billionGrowth RatePoised to grow at a CAGR of 13.4%Forecast Period2024-2031Forecast UnitsValue (USD Billion)Report CoverageRevenue Forecast, Competitive Landscape, Growth Factors, and TrendsSegments CoveredProduct, Delivery Mode, Clinical Trial Phase, End-user, and RegionGeographies CoveredNorth America, Europe, Asia-Pacific, Middle East & Africa, Latin AmericaReport HighlightsUpdated financial information / product portfolio of playersKey Market OpportunitiesGrowing investments in digitization of the healthcare spaceKey Market DriversRising number of clinical trials and emphasis on managing huge volumes of data Ease of Access of Web-Hosted eClinical Solutions Provides it Reign Over All Other Segments Web-hosted eClinical Solutions don't require a substantial infrastructure and are highly affordable for all kinds of institutions, which makes them preferred for all kinds of organizations. Easy customization and cross-platform capabilities of web-hosted solutions are also other benefits that are projected to create new opportunities for market growth via this segment. Huge Volumes of Data Associated with Phase III Clinical Trials Makes them Highly Remunerative Phase III clinical trials are performed at the end of a development cycle when the drug is expected to be made available to the general population. At this stage, the clinical trial deals with huge volumes of data that necessitate the use of a proficient eClinical solution. This phase also involves using data from the current standard treatment to compare with the new medication being tested. High Investments in Medical R&D Helps North America Emerge as the Leading User of eClinical Solutions Investments in the development of novel healthcare products and medications are higher in the North American region than in any other place in the world. The presence of key healthcare organizations and government support for medical R&D are also contributing to the dominance of this region. High incidence of chronic disorders and growing patient population in the United States makes it the prime market for eClinical solution providers in this region. Request Free Customization of this report: https://www.skyquestt.com/speak-with-analyst/eclinical-solutions-market eClinical Solutions Market Insights: Drivers Growing investments in medical R&D Increasing drug approval pipelinesRising demand for personalized treatments Restraints High costs of eClinical Solutions development Lack of awareness regarding benefits of eClinical Solutions use The following are the Top eClinical Solutions Companies: Oracle CorporationMedidata Solutions Inc.Parexel International CorporationBioclinica Inc.OpenClinica DATATRAK International Inc. CRF HealthAdvarra MedNet Solutions Inc. Bio-Optronics Inc. View report summary and Table of Contents (TOC): https://www.skyquestt.com/report/eclinical-solutions-market Key Questions Answered in eClinical Solutions Market Report What drives the global eClinical Solutions market growth? Who are the leading eClinical Solutions providers in the world? Which region leads the demand for eClinical Solutions in the world? This report provides the following insights: Analysis of key drivers (high investments in healthcare R&D, growing demand for personalized treatments), restraints (lack of awareness regarding eClinical Solutions benefits, high costs of development), and opportunities (integration of CDMS and EHR systems to optimize healthcare operational efficiency), influencing the growth of eClinical Solutions market.Market Penetration: All-inclusive analysis of product portfolio of different market players and status of new product launches.Product Development/Innovation: Elaborate assessment of R&D activities, new product development, and upcoming trends of the eClinical Solutions market. Market Development: Detailed analysis of potential regions where the market has potential to grow. Market Diversification: Comprehensive assessment of new product launches, recent developments, and emerging regional markets. Competitive Landscape: Detailed analysis of growth strategies, revenue analysis, and product innovation by new and established market players. Related Reports: Healthcare IT Market Digital Health Market Artificial Intelligence (AI) in Healthcare Market mHealth Market Home Healthcare Market About Us: SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally. We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization has expanded our reach across North America, Europe, ASEAN and Asia Pacific. Mr. Jagraj Singh Skyquest Technology 1 Apache Way, Westford, Massachusetts 01886 USA (+1) 617-230-0741 Email: sales@skyquestt.com Visit Our Website: https://www.skyquestt.com/ Market News and Data brought to you by Benzinga APIs

Benzinga

Thu, 8 Aug, 2:01 PM UTC

Embracing the power of data analytics and AI for clinical trials

Sponsored Content by Innovaderm Research Inc.Reviewed by Olivia FrostDec 10 2024 The clinical trials arena is becoming increasingly data-driven, with demand growing for sponsors to have real-time data access and ongoing updates throughout a study rather than just a final report. The timely provision of clean and accurate information requires employing digital systems that support efficient data handling, analysis, and reporting. Image Credit: ArtemisDiana/Shutterstock.com New technologies such as artificial intelligence (AI) and machine learning (ML) are gradually being adopted for clinical studies, although they remain tools rather than complete solutions. This is especially true in fields such as dermatology and rheumatology, where results often depend on subjective human observations of outcomes rather than quantitative measurements of disease biomarkers. The challenge for the clinical trials sector is how to incorporate ever-evolving digital platforms into their processes to improve data management and streamline operations while delivering high-quality results and maximum value for sponsors. Real-time data enables prompt action As clinical trials increase in complexity, so do the vast data streams that require accurate analysis and interpretation. High-quality data is essential to support evidence-based decision-making; any errors or inconsistencies may cause costly delays or even invalidate the trial. Robust systems for capturing and integrating data are, therefore, vital for success. Historically, data analysis reports have been delivered retrospectively after clinical trials. The downside of this approach is that valuable time has already been lost if inaccuracies are identified or the data is inadequate; the opportunity to adapt the protocol as the study progresses has been missed. These challenges can be addressed by delivering a continuous transparent stream of actionable information. Access to real-time data offers advantages all around, enhancing the quality and responsiveness of the trial. Issues such as recruitment delays in certain demographics, protocol deviations, or preliminary data showing an unexpected adverse effect can be identified and corrected early, driving process efficiency and potentially leading to quicker decision-making, optimized use of resources, more ethical trials, and better patient outcomes. Advanced data management systems that can securely integrate and share live data with sponsors without compromising data integrity or confidentiality are key to achieving this goal. Image Credit: Gorodenkoff/Shutterstock.com From raw data to actionable insights Collating clinical trial data from geographically scattered investigative sites is challenging and can result in inconsistent data formats, incompatible systems, and dispersed data storage, leading to inefficiencies, delays, and even protocol errors. Effective data integration systems can significantly improve this situation and are critical to getting the most out of the powerful data analytics tools now available. Data analytics plays a crucial role in operational efficiency, transforming raw data into actionable insights by identifying patterns and refining methodologies. Where does AI fit in? The power of analytics is being taken further with AI-powered technologies, such as machine learning and predictive analytics. However, it is important to be clear about the differences between these methodologies and their capabilities to truly understand their potential and limitations in the clinical trial arena. AI tools have the potential to help predict issues before they arise, enabling the optimization of resource allocation. They also play a key role in processing and harmonizing the variety of data types collected in modern trials -- from patient-reported outcomes and wearable devices to lab results and electronic health records -- exposing patterns that can inform protocol design and execution. They can also help automate data cleaning and validation, allowing researchers to focus on high-value analysis instead of repetitive sorting. While AI and ML are poised to revolutionize clinical studies in the future, they still have some way to go to be a complete solution. They can analyze vast amounts of data, uncover hidden patterns, and generate valuable insights to enable data-driven decision-making. However, there are still questions surrounding the quality and size of representative data sets that can be used to train these models. As the capabilities of AI and ML continue to evolve and they become more integral to clinical trials, it is essential to maintain a balance between technological innovation and human expertise. AI should be deployed where it can add value, but human judgment remains crucial; AI lacks the contextual understanding necessary to make nuanced decisions about patient care or trial adjustments. CROs adopting AI should take a cautious, controlled approach to ensure reliability, prioritizing accuracy and accountability. This balance between innovation and expertise is vital for the integrity of clinical studies and reflects a commitment to patient safety and ethical practice. It is particularly relevant in disease areas such as dermatology, where patient outcomes are based on subjective endpoints. Process improvements to streamline data flow Whether CROs rely on AI or not, the data stream is the main deliverable, so improving its access, flow, and analysis is often a central focus for process improvement initiatives. Process efficiency is essential for those that operate in niche indications -- such as dermatology and rheumatology specialist Innovaderm -- ensuring the high-quality results and effective cost management that are vital to remaining competitive with larger players. Integrating digital tools into a company's SOPs requires careful consideration to understand exactly what can be achieved and how best to do it. For example, reducing the manual workload associated with data entry or patient recruitment can free up resources that can be redirected toward specialized services, such as specific disease expertise. This focus on efficiency benefits sponsors, too, who receive timely, accurate results from the insights of subject matter experts. Similarly, the use of integrated trial management systems ensures that workflows are smooth and that data flows seamlessly from one department to another, reducing silos and avoiding breakdowns in communication. Integrated systems are particularly valuable when working with external partners, such as investigative sites or sponsors, who need access to relevant data and updates. Image Credit: MUNGKHOOD STUDIO/Shutterstock.com Conclusion Clinical trials are becoming increasingly complex and data-intensive, and CROs must navigate a landscape that demands efficiency, transparency, and high-quality data. AI and data analytics are promising tools that will streamline operations and provide real-time insights to sponsors, but AI, in particular, is just that - a tool and not a complete solution, with human expertise remaining central to the decision-making process. For CROs, particularly those operating in specialized fields like dermatology and rheumatology, the key to success is balancing technological advancements with operational efficiencies. By carefully integrating AI, improving data management processes, and fostering collaborative systems, CROs can meet sponsors' evolving needs, delivering accurate and high-quality data in a timely and efficient manner. As the industry advances, those who can achieve this balance will be well-positioned to deliver trials that benefit both sponsors and patients. About Innovaderm Research Inc. Innovaderm Research Inc. is a specialized CRO with a dual focus on dermatology and rheumatology. They assist biopharmaceutical sponsors in initiating and completing clinical trials. Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

News-Medical.net

Tue, 10 Dec, 6:12 PM UTC

Electronic data capture in resource-limited settings using the lightweight clinical data acquisition and recording system - Scientific Reports

Our prototype system designed for clinical data acquisition and recording of studies is a novel electronic data capture (EDC) software for simple and lightweight data capture in clinical research. Existing software tools are either costly or suffer from very limited features. To overcome these shortcomings, we designed an EDC software together with a mobile client. We aimed at making it easy to set-up, modifiable, scalable and thereby facilitating research. We wrote the software in R using a modular approach and implemented existing data standards along with a meta data driven interface and database structure. The prototype is an adaptable open-source software, which can be installed locally or in the cloud without advanced IT-knowledge. A mobile web interface and progressive web app for mobile use and desktop computers is added. We show the software's capability, by demonstrating four clinical studies with over 1600 participants and 679 variables per participant. We delineate a simple deployment approach for a server-installation and indicate further use-cases. The software is available under the MIT open-source license. Conclusively the software is versatile, easily deployable, highly modifiable, and extremely scalable for clinical studies. As an open-source R-software it is accessible, open to community-driven development and improvement in the future. Biomedical studies rely on methodical data acquisition and processing. EDC software is essential to biomedical research since it greatly facilitates systematic data acquisition and processing enabling meaningful analysis and relevant insights. Furthermore, high-quality data acquisition and handling is the key to reliable research results. Modern EDC software must serve vastly diverse needs of biomedical studies while protecting data integrity and promoting transparent, reproducible, and reliable research. The process of data recording, using the electronic Case Report Form (eCRF) integrated into the EDC software needs to be as easy as possible, facilitating data acquisition both by study personal and by patients when filling out patient related outcome forms. In general, use of an EDC software in contrast to spread sheet solutions improves data quality whilst reducing time consumption. The quality and comprehensiveness of data is ensured by detection of missing fields or inability to complete the submission form, a central aspect of the eCRF. An important feature of EDC software, especially with interventional studies, is the possibility of real data analysis and review, whilst monitoring the study outcome thus being able to interfere whenever a group of patients might be harmed by the intervention studied. Most current EDC programs are published under proprietary licenses. These include some of the most widely used EDC software in academic research, such as REDCap. Their usage and distribution are subject to fees or specific conditions and their source code is not publicly available. Customizations and deployment of proprietary software is costly and/or bound to strict limitations. When customizations are not easily available to third parties, scientific reproducibility is impaired. Especially, data exchange and compatibility are of major importance in medical research but are often impaired by vendor-specific data architecture. Many research groups have published innumerous studies using the REDCap software, but a head-to-head analysis against other proprietary software is not available. The most frequent burdens in the application especially involve the setup of the system since advanced computing skills are needed to run in on the local computer which often includes extra local setup fees. Yet another popular eCRF software published under a proprietary license is soscisurvey, which is mostly used for simple online surveys. It is difficult to use when more than one time point is assessed. Important and frequent limitations of many available EDC systems are restrictions in creating versions of the database in an active study. Modifying the meta data (e.g. adding variables or visits) to a study protocol after an amendment requires archiving the existing database and a complete reset of the database. Other commonly issues include the lack of auditability and security-concerns of the EDC software owing to many solutions being programmed rather long ago with constantly changing standards. An important alternative to proprietary programs is open-source software. Its source code is available to the public domain under a variety of open-source licenses. Generally, open-source licenses allow the use, study, adaptation, and distribution of the source code and the software itself to everybody and for any use. Some of the most widely used programming languages, software packages and operating systems such as C#, R, Ubuntu or Android are published under open-source licenses. In the scientific context, open source-software has important advantages: publicly available source code makes open-source software transparent. Adaption and scientific analyses of open-source software are viable and not limited to license constraints. Publicly funded software development stays available to the public. Developer communities can maintain and improve the software as needed. Unfortunately, open-source EDC programs like OpenClinica often suffer from limited features in the open-source branch. Customizations and deployment of these programs require advanced software engineering skills, due to advanced programming languages and complex software architectures. Furthermore, more recent advances such as federated learning or artificial intelligence can't be deployed. Getting started with a clinical study might require substantial resources and time for customizing and setting up current proprietary and open-source EDC systems. For many small research projects, these resources are not affordable. In consequence, such projects do not use EDC software but rather rely on spreadsheet-programs and paper-based forms for patient questionnaires. This jeopardizes data quality and impairs collaborative multicenter research for small projects or in low-budget settings. To address these problems, we designed a new prototype for an open-source EDC software and an accompanying mobile client.

Nature

Sat, 17 Aug, 10:02 AM UTC

ClinicalTrials.EU platform rolled out across Europe

LONDON, Sept. 25, 2024 (GLOBE NEWSWIRE) -- The European Clinical Trials Information Network (ClinicalTrials.EU) has today announced its official rollout across the continent. The patient-centric platform aims to solve one of the biggest challenges in medical and pharmaceutical research - the recruitment of suitable patients. It will do this by democratising patient access to clinical trials and arming them with the latest, most comprehensive information on current trials in seven European languages. Currently, over 15,500 clinical trials are registered in Europe in the pre-recruitment or recruitment phase. However, as many as 80 percent of them will have problems obtaining or maintaining a sufficient sample, leading to delays, increased costs or abandonment of the project. On the flipside, 86% of patients are not captured by the traditional clinical trial recruitment model [3]. ClinicalTrials.EU provides a credible and trustworthy link between researchers and patients. Research information is aggregated from multiple public and commercial sources and conveyed in an understandable, engaging and patient-friendly way. Founder, Dr. Łukasz Izbicki, previously founded Farmacja.net Group, which was taken over last year by IQVIA, a global supplier of advanced analytical and technological solutions for the pharmaceutical sector. He said, of the project: "Our mission at ClinicalTrials is simple. To connect research centers actively working on rare and serious diseases and illnesses with patients actively seeking appropriate therapies and create "Clinical Trials: Easily Understood"." "Until now there has been no single place where both parties could meet with confidence and find comprehensive information in a number of different languages. This has been a huge barrier in the development of treatments, as often, the absolute numbers of patients for rare diseases might be very small and geographically diverse and it can be challenging to locate and engage with them. As many as 80% of trials face challenges with patient recruitment." Recruiting patients for clinical trials is ineffective and expensive: often researchers rely on existing patient databases or referrals from doctors in their networks. This can mean many potential patients missing out on suitable trials. ClinicalTrials.EU aims to democratise access by putting the power in the hands of the patient and allowing them to find the best treatment with the help of AI pre-screening. This in turn, effectively gives researchers access to patients who have self-selected and therefore more likely to be suitable for the trials. The acceleration of the recruitment process means trials can be implemented faster and the path to innovative therapies coming to market is also made quicker and easier. It also opens the way to decentralized research, allowing most or all research processes to be transferred to the patient's home. This is especially important for people who cannot, for various reasons, participate in a clinical trial conducted in another city or country. This model has only recently appeared on the European market, but represents almost 25% of the clinical trials market in the US due to the convenience of patients, significant savings for sponsors, and the facilitation of the recruitment process. The European clinical trials market market in this area was valued at over USD 6 billion in 2023 and, according to forecasts, it will reach USD 9.6 billion by 2029 with an average annual growth rate in 2024-2029 (CAGR) of 7%. In the first six months when the platform was still in beta phase, it had already attracted considerable support and traction within the industry. It is now listed among major market players in partnership with NORD - US Rare Disease Organization and is a member of the EU Cross Border Clinical Trials Initiative (EU-X-CT), a joint EU Parliament and EFPICA (business) initiative. It also co-operates with a number of Patients' Advocacy Groups, is working with the Polish Medical Research Agency and partnering with academic sites on non commercial trials, as well as co-operating commercially with Sponsors, CROs and Sites. Dr. Izbicki added: "We are excited at the amount of traction we have already seen prior to a formal rollout. And this is just the start! Currently, we aggregate data for the database from publicly available sources, we have enabled individual sponsors and research centers to post information about their projects on the platform. We have acquired the first commercial customers in this area and we are seeing huge interest in this area. "By the end of the year, we plan to start working with the 30 largest CROs (Contract Research Organizations) globally, which represent around 10 percent of the clinical trials market. Our mission is to increase access to clinical trials for patients who, for various reasons, are not treated as effectively as they could be." Prof. Wojciech Fendler, Head of the Polish Medical Research Agency, concluded: "Clinical trials are critical for developing new therapies, and the success of recruitment depends on providing both patients and researchers with a unified platform as ClinicalTrials.EU that facilitates access to information and collaboration, which until now has been scattered across various sources." A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e22840d2-2046-4993-a76b-0f18d38ea54f CONTACT Fiona Chow COMPANY ClinicalTrials.EU EMAIL: fiona.chow@goadi.co.uk WEB: https://clinicaltrials.eu/ Market News and Data brought to you by Benzinga APIs

Benzinga

Wed, 25 Sept, 2:00 PM UTC

Similar products

i2b2

i2b2 is an open-source software enabling researchers to leverage existing clinical data for discovery research.

Free

Labfolder

Labfolder is a cloud-based Electronic Lab Notebook (ELN) that enables scientists to optimize their research data management and laboratory processes.

Contact for Pricing

Unlearn

Unlearn is a digital platform that uses artificial intelligence to create digital clones of human physiological responses, helping in drug development and clinical trials.

Contact for Pricing

MDClone

MDClone is an AI-powered tool designed to democratize healthcare data, allowing organizations to utilize their in-house data to improve patient outcomes.

Freemium

DrugCard

DrugCard is an AI-enabled platform designed to automate and enhance local literature screening for pharmacovigilance, offering efficient and multilingual support to streamline drug safety processes.

Paid

Your one-stop AI hub

The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.

Creative and design

OpenClinica

Contact for Pricing

About OpenClinica

Related fields

Related News

Similar products

i2b2

Labfolder

Unlearn

MDClone

DrugCard

Your one-stop AI hub

The Outpost

Keep in touch